雌激素受体β在乳腺癌预后和治疗中的作用
Ana Božović1, Milica Nedeljković2, Bojana Kožik1
1Department for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, Serbia.
Maturitas
|November 4, 2025
概括
雌激素受体β (ERβ) 甲基化可以预测乳腺癌治疗反应. 高ERβ甲基化与他莫西芬的治疗结果更好相关,而低甲基化表明放射治疗的生存时间更短.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 大约30%的乳腺癌患者表现出对辅助他莫西芬治疗的耐药性.
- 目前的治疗决定依赖于已知的生物标志物,如雌激素受体α,孕激素受体和HER2.
- 需要新的生物标志物来改善乳腺癌预后和治疗选择.
研究的目的:
- 研究雌激素受体β (ERβ) 与乳腺癌预后之间的关联.
- 为了确定ERβ是否与乳腺癌患者的治疗反应有关.
- 探索ERβ表达和甲基化作为预测生物标志物的作用.
主要方法:
- 从118名乳腺癌患者 (2002-2022) 的临床病理学,治疗和生存数据的回顾性分析.
- 评估ERβ蛋白,ERβ1和delta5变体mRNA,以及ERβ促进体甲基化指数.
- 卡普兰-梅尔和日志等级测试被用于生存分析.
主要成果:
- 在ERβ甲基化指数高的患者中,他莫西芬治疗与改善的整体存活率 (p=0.001) 和无病存活率 (p=0.033) 相联系.
- 相反,在ERβ甲基化指数较低的患者中,放射治疗与无病存活率降低有关 (p=0.037).
- 这些发现突出了基于ERβ甲基化状态的潜在差异性治疗反应.
结论:
- 雌激素受体β (ERβ) 表达和甲基化可能作为乳腺癌的显著预后标志物.
- ERβ状态可以为定制治疗决策提供有价值的信息.
- 这些产生假设的发现需要在更大的前性研究中进行验证.
相关概念视频
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:20The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
01:15Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
01:21Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K